New drug RC88 shows promise for advanced cancers in early trial

NCT ID NCT05508334

Completed Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RC88 (an injectable drug)
What this could lead to: If successful, RC88 could offer a new treatment option for people with advanced solid tumours who have not responded to standard therapies.
What could go wrong: This is an early-phase study with only 41 participants, so results may not apply to everyone. The main goal is safety, not yet proving effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS

Contacts and locations

Locations

Remegen

Beijing, Beijing Municipality, China
Remgenen

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.